⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94573 | 1.00 | — | — | |
| Dimethyl Sulfoxide SCHEMBL9815445 | 0.91 | — | — | |
| SCHEMBL2958233 | 0.72 | LMNA (0.36) | — | |
| SCHEMBL28437196 | 0.72 | LMNA (0.36) | — | |
| SCHEMBL3041976 | 0.67 | — | — | |
| SCHEMBL16556327 | 0.64 | G6PD (0.33) | — | |
| SCHEMBL11584532 | 0.64 | — | — | |
| SCHEMBL15974801 | 0.64 | — | — | |
| SCHEMBL237697 | 0.62 | — | — | |
| SCHEMBL2471184 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819630-B | Method for preparing high-charge nanocellulose | 浙江大学衢州研究院 | 2024-07-05 | — | — | CN | claimed |
| EP-2478049-A1 | A POLYMER SUPPORT | University of Cape Town (ZA) | 2012-07-25 | — | — | EP | claimed |
| WO-2011083360-A1 | A POLYMER SUPPORT | UNIVERSITY OF CAPE TOWN (ZA) | 2011-07-14 | — | — | WO | claimed |
| WO-2007047426-A2 | BIOACTIVE DELIVERY MATRIX COMPOSITIONS AND METHODS | MEDTRONIC, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| EP-0787228-B1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMW SCIENT IND RES ORG (AU) | 2003-01-02 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-6113678-A | Hot melt inks containing polyanhydrides | XEROX CORPORATION (US) | 2000-09-05 | — | — | US | claimed |
| US-5928383-A | ANNEALING THE FABRIC AT FROM 70 DEGREES C. TO 160 DEGREES C. AT A REGAIN OF BETWEEN 10% AND 25% FOR A PERIOD GREATER THAN ABOUT 10 MINUTES WHEREIN THE FABRIC IS ANNEALED IN THE PRESENCE OF A GAS WHICH ENHANCES THE DISULFIDE INTERCHANGE | THE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1999-07-27 | — | — | US | claimed |
| EP-0787228-A4 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMW SCIENT IND RES ORG (AU) | 1998-09-02 | — | — | EP | claimed |
| EP-0683822-A4 | PREPARATION OF PHOTOPROTEIN CONJUGATES AND METHODS OF USE THEREOF. | SEALITE SCIENCES INC (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0787228-A1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1997-08-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| WO-1996012057-A1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1996-04-25 | — | — | WO | claimed |
| EP-0683822-A1 | PREPARATION OF PHOTOPROTEIN CONJUGATES AND METHODS OF USE THEREOF | SEALITE SCIENCES, INC. (US) | 1995-11-29 | — | — | EP | claimed |
| WO-1994018342-A1 | PREPARATION OF PHOTOPROTEIN CONJUGATES AND METHODS OF USE THEREOF | SEALITE SCIENCES, INC. (US) | 1994-08-18 | — | — | WO | claimed |
| JP-63152979-A | — | — | None | — | — | JP | disclosed |
| CN-122006676-A | Nanoparticle for enriching low-abundance protein in blood plasma, preparation method thereof and application thereof in early cancer screening | 中国科学院长春应用化学研究所 | 2026-05-12 | — | — | CN | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4341435-A1 | METHODS OF BASE CALLING NUCLEOBASES | Illumina, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4304659-A1 | PROTEIN-DRUG CONJUGATES FOR ANTIVIRAL THERAPY | CIDARA THERAPEUTICS, INC. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2024010810-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-4297796-A1 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023175043-A1 | METHODS OF BASE CALLING NUCLEOBASES | ILLUMINA, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175026-A1 | METHODS OF DETERMINING SEQUENCE INFORMATION | ILLUMINA, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175042-A1 | PARALLEL SAMPLE AND INDEX SEQUENCING | ILLUMINA, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175024-A1 | PAIRED-END SEQUENCING | ILLUMINA, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023107622-A1 | PARALLEL SAMPLE AND INDEX SEQUENCING | ILLUMINA, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| EP-4192512-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4028392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4025256-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4017529-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3982994-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3982993-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3947667-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241398-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| EP-3921382-A1 | DEGRADABLE URETHANE AND URETHANE-UREA SYSTEMS | LANXESS Corporation (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11135182-B2 | Affinity medicant conjugates | AF CHEMICALS, LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210299063-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3856778-A1 | SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES | The Medical College of Wisconsin, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3846846-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | Cidara Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3813883-A1 | CONJUGATES | Glykos Biomedical Oy (FI) | 2021-05-05 | — | — | EP | disclosed |
| WO-2021081515-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210077425-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021046549-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021035177-A2 | VARIANT FC DOMAINS AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2020252396-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252393-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020198264-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020163674-A1 | DEGRADABLE URETHANE AND URETHANE-UREA SYSTEMS | LANXESS SOLUTIONS US INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020068774-A1 | SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020002765-A1 | CONJUGATES | GLYKOS BIOMEDICAL OY (FI) | 2020-01-02 | — | — | WO | disclosed |
| CN-104650237-B | It a kind of cross-linking antibody and its is applied in immune detection | 英科隆生物技术（杭州）有限公司 | 2019-08-20 | — | — | CN | disclosed |
| CN-110064053-A | The preparation and medication of protein matrix vaccines and this vaccine | 哈佛大学校长及研究员协会 | 2019-07-30 | — | — | CN | disclosed |
| CN-101553246-B | Protein matrix vaccines and methods of making and administering such vaccines | 哈佛大学校长及研究员协会 | 2019-05-21 | — | — | CN | disclosed |
| CN-104650239-B | A kind of antibody and its application in Toxoplasma immune detection | 英科隆生物技术（杭州）有限公司 | 2018-08-07 | — | — | CN | disclosed |
| CN-108350487-A | compound and system for improving signal detection | 加利福尼亚太平洋生物科学股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3350350-A1 | COMPOUNDS AND SYSTEMS FOR IMPROVING SIGNAL DETECTION | Pacific Biosciences of California, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2018128826-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| CN-104650238-B | Human cytomegalovirus cross-linking antibody and its application in immunity detection reagent | 艾康生物技术(杭州)有限公司 | 2018-03-06 | — | — | CN | disclosed |
| CN-104650236-B | A kind of heterologous cross-linking agent and its application in rubella virus detects | 英科隆生物技术（杭州）有限公司 | 2018-02-23 | — | — | CN | disclosed |
| WO-2018006063-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| CN-107469085-A | Treat method, composition and the kit of pain and itch | 哈佛大学校长及研究员协会 | 2017-12-15 | — | — | CN | disclosed |
| CN-103933572-B | Treat method, composition and the kit of pain and itch | 哈佛大学校长及研究员协会 | 2017-10-13 | — | — | CN | disclosed |
| CN-106167510-A | A kind of double selenium polypeptide and preparation method thereof | 苏秀兰 | 2016-11-30 | — | — | CN | disclosed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| EP-2885313-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | The Regents of The University of California (US) | 2015-06-24 | — | — | EP | disclosed |
| CN-103933572-A | Methods, compositions, and kits for treating pain and pruritis | HARVARD COLLEGE | 2014-07-23 | — | — | CN | disclosed |
| WO-2014031575-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2513225-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | Interface Biologics Inc. (CA) | 2012-10-24 | — | — | EP | disclosed |
| EP-2478049-A1 | A POLYMER SUPPORT | University of Cape Town (ZA) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012021733-A2 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011083360-A1 | A POLYMER SUPPORT | UNIVERSITY OF CAPE TOWN (ZA) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011072398-A1 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS | INTERFACE BIOLOGICS, INC. (CA) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011005510-A2 | PEPTIDE CONJUGATES AND USES THEREOF | CERAPEDICS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010114921-A1 | EPH RECEPTOR LIGANDS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010059880-A2 | PHOTO-INDUCED DAMAGE MITIGATING AGENTS AND PREPARATION AND METHODS OF USE THEREOF | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| CN-101610789-A | Methods, compositions and kits for treating pain and itch | HARVARD COLLEGE (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2101819-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2078086-A1 | IMMUNOGENIC AFFINITY-CONJUGATED ANTIGEN SYSTEMS BASED ON PAPAYA MOSAIC VIRUS AND USES THEREOF | Folia Biotech Inc. (CA) | 2009-07-15 | — | — | EP | disclosed |
| EP-2056871-A2 | PROTEIN MATRIX VACCINES AND METHODS OF MAKING AND ADMINISTERING SUCH VACCINES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008151389-A1 | CHEMICALLY MODIFIED MACROMOLECULES | MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) | 2008-12-18 | — | — | WO | disclosed |
| EP-1940386-A2 | WORTMANNIN CONJUGATES AND USES THEREOF | Beth Israel Deaconess Medical Center (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008063603-A2 | METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008058369-A1 | IMMUNOGENIC AFFINITY-CONJUGATED ANTIGEN SYSTEMS BASED ON PAPAYA MOSAIC VIRUS AND USES THEREOF | FOLIA BIOTECH INC. (CA) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008021076-A2 | PROTEIN MATRIX VACCINES AND METHODS OF MAKING AND ADMINISTERING SUCH VACCINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1883410-A2 | ANTIBODY OR ANTIBODY FRAGMENT COUPLED WITH AN IMMUNOGENIC AGENT | INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER (IFREMER) (FR) | 2008-02-06 | — | — | EP | disclosed |
| CN-100338465-C | Enzyme-protein composition | NIKIYO KK (JP) | 2007-09-19 | — | — | CN | disclosed |
| US-20070197430-A1 | Conjugates And Therapeutic Uses Thereof | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-08-23 | — | — | US | disclosed |
| WO-2007086943-A2 | WORTMANNIN CONJUGATES AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070161121-A1 | COMPOSITIONS FOR SEPARATION OF A PLURALITY OF DISTINCT TARGETS FROM A SAMPLE | SIGMA ALDRICH (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161124-A1 | Compositions for separation of a plurality of distinct targets from a sample | SIGMA-ALDRICH CO. | 2007-07-12 | — | — | US | disclosed |
| EP-1806584-A1 | Compositions for separation of a plurality of distinct targets from a sample | Sigma-Aldrich Co. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007041677-A9 | SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF | COMBINATORX INC (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007054977-A2 | METHOD AND COMPOSITION FOR SKIN DEPIGMENTATION | BRAIN N' BEYOND BIOTECH PVT. LTD. (IN) | 2007-05-18 | — | — | WO | disclosed |
| EP-1781689-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | The Walter and Eliza Hall Institute of Medical Research (AU) | 2007-05-09 | — | — | EP | disclosed |
| WO-2007041584-A2 | IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041463-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041677-A2 | SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006125921-A2 | ANTIBODY OR ANTIBODY FRAGMENT COUPLED WITH AN IMMUNOGENIC AGENT | INSTITUT FRANCAIS DE RECHERCHE POUR L'EXPLOITATION DE LA MER IFREMER (FR) | 2006-11-30 | — | — | WO | disclosed |
| EP-1562627-A4 | CORTICOSTEROID CONJUGATES AND USES THEREOF | MCLEAN HOSPITAL CORP (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006000034-A1 | CONJUGATES AND THERAPEUTIC USES THEREOF | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005123761-A1 | GnRH ANALOGS BACKBONE CYCLIZED THROUGH METAL COMPLEXATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-12-29 | — | — | WO | disclosed |
| EP-1562627-A2 | CORTICOSTEROID CONJUGATES AND USES THEREOF | The McLean Hospital Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1539216-A2 | LABELLED SOMATOSTATIN ANALOGS BACKBONE CYCLIZED THROUGH METAL COMPLEXATION | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004017904-A2 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004000204-A2 | LABELLED SOMATOSTATIN ANALOGS BACKBONE CYCLIZED THROUGH METAL COMPLEXATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-12-31 | — | — | WO | disclosed |
| EP-1356297-A2 | METHODS AND KITS FOR SEQUENCING POLYPEPTIDES | THE PROCTER & GAMBLE COMPANY (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-0787228-B1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMW SCIENT IND RES ORG (AU) | 2003-01-02 | — | — | EP | disclosed |
| US-6376151-B1 | HYDROXYPOLYAMIDES | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2002-04-23 | — | — | US | disclosed |
| WO-2002008767-A2 | METHODS AND KITS FOR SEQUENCING POLYPEPTIDES | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1137760-A1 | BLEACHING ENZYMES AND DETERGENT COMPOSITIONS COMPRISING THEM | UNILEVER N.V. (NL) | 2001-10-04 | — | — | EP | disclosed |
| CN-1306860-A | Composition and preparation of human tumor antigen-mycobacterium heat shock protein tumor vaccine | UNIV DALIAN MEDICAL (CN) | 2001-08-08 | — | — | CN | disclosed |
| CN-1300942-A | Enzyme-protein composition | NIKIYO KK (JP) | 2001-06-27 | — | — | CN | disclosed |
| EP-1096316-A1 | POSITIVE RESIST COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000036094-A1 | BLEACHING ENZYMES AND DETERGENT COMPOSITIONS COMPRISING THEM | UNILEVER N.V. (NL) | 2000-06-22 | — | — | WO | disclosed |
| EP-0988360-A2 | BLEACHING ENZYMES | UNILEVER N.V. (NL) | 2000-03-29 | — | — | EP | disclosed |
| EP-0977600-A2 | CONTRAST AGENTS | NYCOMED IMAGING A/S (NO) | 2000-02-09 | — | — | EP | disclosed |
| US-5928383-A | ANNEALING THE FABRIC AT FROM 70 DEGREES C. TO 160 DEGREES C. AT A REGAIN OF BETWEEN 10% AND 25% FOR A PERIOD GREATER THAN ABOUT 10 MINUTES WHEREIN THE FABRIC IS ANNEALED IN THE PRESENCE OF A GAS WHICH ENHANCES THE DISULFIDE INTERCHANGE | THE COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1999-07-27 | — | — | US | disclosed |
| WO-1998056885-A2 | BLEACHING ENZYMES | UNILEVER N.V. (NL) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998047541-A1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-10-29 | — | — | WO | disclosed |
| EP-0787228-A4 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMW SCIENT IND RES ORG (AU) | 1998-09-02 | — | — | EP | disclosed |
| EP-0828552-A4 | PROCESS FOR RECOVERY OF METAL IONS | UNIV CALIFORNIA (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0842197-A2 | BROAD SPECIFICITY ANTIBODIES | THE MINISTER OF AGRICULTURE FISHERIES AND FOOD IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN (GB) | 1998-05-20 | — | — | EP | disclosed |
| EP-0828552-A1 | PROCESS FOR RECOVERY OF METAL IONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0787228-A1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1997-08-06 | — | — | EP | disclosed |
| WO-1997005170-A2 | BROAD SPECIFICITY ANTIBODIES | THE MINISTER OF AGRICULTURE FISHERIES & FOOD IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996038220-A1 | PROCESS FOR RECOVERY OF METAL IONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996012057-A1 | CHEMICALLY ASSISTED PROTEIN ANNEALING TREATMENT | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1996-04-25 | — | — | WO | disclosed |
| EP-0637385-A1 | IMMOBILIZATION OF SPECIFIC BINDING ASSAY REAGENTS | DADE INTERNATIONAL INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994019693-A1 | IMMOBILIZATION OF SPECIFIC BINDING ASSAY REAGENTS | BAXTER DIAGNOSTICS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5053453-A | Protein covalently bound to support material | BAXTER INTERNATIONAL INC. (US) | 1991-10-01 | — | — | US | disclosed |
| US-4925945-A | Certain -N-(amino benzoyl)-N'-(pyridyldithioalkanoyl)-hydrazines and derivatives thereof | BOEHRINGER MANNHEIM GMBH (DE) | 1990-05-15 | — | — | US | disclosed |
| EP-0367489-A2 | Thromboresistant materials and methods for making same | BAXTER INTERNATIONAL INC. (US) | 1990-05-09 | — | — | EP | disclosed |
| EP-0326907-A1 | Polypeptide, DNA and its use | Takeda Chemical Industries, Ltd. (JP) | 1989-08-09 | — | — | EP | disclosed |
| EP-0303229-A2 | Method of high sensitivity immunoassay | Ishikawa, Eiji (JP) | 1989-02-15 | — | — | EP | disclosed |
| EP-0288687-A2 | Monoclonal antibody, hybridoma, their production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-11-02 | — | — | EP | disclosed |
| EP-0281822-A2 | Basic fibroblast growth factor mutein, DNA and its use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-14 | — | — | EP | disclosed |
| EP-0252951-A4 | TECHNETIUM-ANTIBODY CONJUGATE. | UNIV MELBOURNE (AU) | 1988-09-07 | — | — | EP | disclosed |
| JP-S63152979-A | REAGENT COMPOSITION HAVING DITHIOL GROUP | TOYO JOZO CO LTD | 1988-06-25 | — | — | JP | disclosed |
| EP-0252951-A1 | TECHNETIUM-ANTIBODY CONJUGATE | THE UNIVERSITY OF MELBOURNE (AU) | 1988-01-20 | — | — | EP | disclosed |
| WO-1987004164-A1 | TECHNETIUM-ANTIBODY CONJUGATE | THE UNIVERSITY OF MELBOURNE (AU) | 1987-07-16 | — | — | WO | disclosed |
| US-4298686-A | HIGH SENSITIVITY, AUTOMATIC | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1981-11-03 | — | — | US | disclosed |
| US-4298686-A | HIGH SENSITIVITY, AUTOMATIC | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1981-11-03 | — | — | US | disclosed |